Skip to main content
Neuronostics logo

Neuronostics

Bristol, United KingdomFounded 2018

  • Seed
  • Epilepsy

Neuronostics develops mathematical modelling approaches to improve how neurological conditions are diagnosed, treated, and monitored. The company is advancing digital biomarkers with a mission to improve life for people with neurological conditions, including through work focused on epilepsy diagnosis.

Raised
$10.2M
Jun 2026
Seed
Investors
11
Founded
2018
Employees
11–50

reccy insights

Recent highlights

Neuronostics’ clearest recent financing milestone came on Jun 30, 2026, when it raised a $3,969,866 seed round led by Empirical Ventures and The FSE Group. On the same date, it also received a $529,315 Innovate UK grant. The seed round followed a $2,654,189 seed raise on Apr 5, 2024 led by Ascension Life Fund, extending a funding history that includes earlier seed rounds and grants. In neurological care, the company has pursued a US collaboration with Stratus. The partnership announcement dated Jul 15, 2025 described work to validate and advance BioEP for epilepsy diagnosis and treatment; a 2026 update describes integration and scalable US deployment as subject to regulatory clearance. In November 2025, Neuronostics received the Most Transformative Healthtech Company Award at the OBN Awards for its neurology decision-support software. The company’s record also includes a board-related change announced on Jul 15, 2025: Charlie Alvarez, CEO of Stratus, was to join the Neuronostics board as part of the alliance. Current hiring signals include software engineering and product management roles. Taken together, these milestones indicate continued financing, external recognition, and efforts to prepare BioEP for wider clinical use, while US deployment remains dependent on regulatory clearance.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Neuronostics distinct

  1. 01Uses mathematical modelling to support diagnosis, treatment, and monitoring of neurological conditions.
  2. 02Focuses on digital biomarkers and epilepsy diagnosis, including EEG-based seizure assessment.
  3. 03BioEP is designed to analyze EEG data for epilepsy diagnosis even when epileptiform activity is not present.
  4. 04Works with healthcare professionals, researchers, and people with lived experience of neurological conditions.
  5. 05Emphasizes scientific rigour, academic peer review, and critique from external experts.

Technology & products3

  • BioEP

    A cloud-based decision-support tool that uses mathematical modelling to analyze EEG data for epilepsy diagnosis, including when no epileptiform activity is present.

  • EEG Reading Service

    A remote EEG reading service in which NHS-qualified neurophysiologists analyze EEG data and provide clinical reports to support research.

  • ConnectEP

    A mobile app in development for people with epilepsy to record seizures, medications, and lifestyle events and generate reports for healthcare appointments.

Recent updates7

  • Oct 20, 2026Award

    Emanuela De Falco awarded Future Leaders Fellowship to develop EEG tools for traumatic brain injury

    neuronostics.com
  • Oct 1, 2026Product launch

    BioEP is now available to the NHS through G-Cloud 15 and the AI DPS

    neuronostics.com
  • Jun 30, 2026Partnership

    Neuronostics formed a strategic partnership with Stratus, described as the largest EEG services provider in the US, to integrate and position BioEP for scalable US deployment, subject to regulatory clearance.

    startupmag.co.uk

Funding

$10.2M disclosed
11 investors

About Neuronostics

Products
BioEP, EEG Reading Service, ConnectEP
Leadership
John Terry, Managing Director
Focus areas
NeuroTechnology, digital health, diagnostics, biotech, research tools, clinical research, neurology, epilepsy
Headquarters
Bristol, United Kingdom
Founded
2018
Employees
11–50
Patents granted
3
Trademarks
2